Bristol UFT oral anticancer agent NDA filing projected for 1998 under licensing agreement with Taiho.
Executive Summary
BRISTOL PROJECTS 1998 NDA FILING FOR UFT FOR COLORECTAL CANCER under a licensing agreement with Taiho Pharmaceutical announced May 10. Under the agreement, Bristol-Myers Squibb will complete Phase III studies of the oral anticancer agent for the colorectal cancer indication and other indications which have not been identified. Bristol will have exclusive rights to the product throughout the world, except in Japan, Spain and several Asia-Pacific countries.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth